Evidence map›Paper›PMID 38987822›Full record

ArticleJournal of translational medicine2024

Identification and bioinformatic characterization of a serum miRNA signature for early detection of laryngeal squamous cell carcinoma.

Michela Falco, Chiara Tammaro, Alessia Maria Cossu, Takashi Takeuchi, Rossella Tufano, Michele Ceccarelli, Giuseppe Scafuro, Silvia Zappavigna, Anna Grimaldi, Marianna Scrima and 11 more

Abstract read
In one paragraph

Article in Journal of translational medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Michela Falco *Laboratory of Molecular and Precision Oncology, BIOGEM Scarl, Institute of Genetic Research, 83031, Ariano Irpino, Italy.
Chiara Tammaro *Department of Precision Medicine, University of Campania "Luigi Vanvitelli", 80138, Naples, Italy.
Alessia Maria CossuLaboratory of Molecular and Precision Oncology, BIOGEM Scarl, Institute of Genetic Research, 83031, Ariano Irpino, Italy.
Takashi TakeuchiLaboratory of Molecular and Precision Oncology, BIOGEM Scarl, Institute of Genetic Research, 83031, Ariano Irpino, Italy.
Rossella TufanoLaboratory of Bioinformatics and Computational Biology, BIOGEM Institute of Molecular Biology and Genetics, 83031, Ariano Irpino, Italy.
Michele CeccarelliLaboratory of Bioinformatics and Computational Biology, BIOGEM Institute of Molecular Biology and Genetics, 83031, Ariano Irpino, Italy.
Giuseppe ScafuroDepartment of Precision Medicine, University of Campania "Luigi Vanvitelli", 80138, Naples, Italy.
Silvia ZappavignaDepartment of Precision Medicine, University of Campania "Luigi Vanvitelli", 80138, Naples, Italy.
Anna GrimaldiU.P. Cytometric and Mutational Diagnostics, AOU Policlinico, University of Campania "Luigi Vanvitelli", Via Luciano Armanni 5, 83031, Naples, Italy.
Marianna ScrimaLaboratory of Molecular and Precision Oncology, BIOGEM Scarl, Institute of Genetic Research, 83031, Ariano Irpino, Italy.
Alessandro OttaianoIstituto Nazionale Tumori Di Napoli, IRCCS "G. Pascale", Via M. Semmola, 80131, Naples, Italy.
Giovanni SavareseAMES, Centro Polidiagnostico Strumentale, 80013, Naples, Italy.
Antonio FicoAMES, Centro Polidiagnostico Strumentale, 80013, Naples, Italy.
Massimo MesolellaUnit of Otorhinolaryngology, Department of Neuroscience, Reproductive Sciences and Dentistry, Federico II University of Naples, Via Gaetano Filangieri, 36, 80131, Naples, Italy.
Morena FasanoDepartment of Precision Medicine, University of Campania "Luigi Vanvitelli", 80138, Naples, Italy.
Giovanni MottaENT Department, L. Vanvitelli University, 80131, Naples, Italy.
Eva Aurora MassimillaENT Department, L. Vanvitelli University, 80131, Naples, Italy.
Raffaele AddeoOncology Operative Unit, Hospital of Frattamaggiore, ASLNA-2NORD, 80020, Naples, Italy.
Filippo RicciardielloDivision of Otorhinolaryngology, "A. Cardarelli" Hospital, 80131, Naples, Italy.
Michele CaragliaLaboratory of Molecular and Precision Oncology, BIOGEM Scarl, Institute of Genetic Research, 83031, Ariano Irpino, Italy. michele.caraglia@unicampania.it.
Gabriella MissoDepartment of Precision Medicine, University of Campania "Luigi Vanvitelli", 80138, Naples, Italy. gabriella.misso@unicampania.it.ORCID 0000-0002-7787-2531

Funding

Ministero della Salute PNRR-MAD-2022-12375755Ministero dello Sviluppo Economico MISE F/310034/01-03/C56 PROJECT ACRONYM:EPI-METUniversità degli Studi della Campania Luigi Vanvitelli 834.2022 PROJECT ACRONYM: miRTALENTUniversità degli Studi della Campania Luigi Vanvitelli DR 509.2022
6 · The paper itself

Abstract

backgroundThe growing understanding of cancer biology and the establishment of new treatment modalities has not yielded the expected results in terms of survival for Laryngeal Squamous Cell Cancer (LSCC). Early diagnosis, as well as prompt identification of patients with high risk of relapse would ensure greater chance of therapeutic success. However, this goal remains a challenge due to the absence of specific biomarkers for this neoplasm.

methodsSerum samples from 45 LSCC patients and 23 healthy donors were collected for miRNA expression profiling by TaqMan Array analysis. Additional 20 patients and 42 healthy volunteers were included for the validation set, reaching an equal number of clinical samples for each group. The potential diagnostic ability of the such identified three-miRNA signature was confirmed by ROC analysis. Moreover, each miRNA was analyzed for the possible correlation with HNSCC patients' survival and TNM status by online databases Kaplan-Meier (KM) plotter and OncomiR. In silico analysis of common candidate targets and their network relevance to predict shared biological functions was finally performed by PANTHER and GeneMANIA software.

resultsWe characterized serum miRNA profile of LSCC patients identifying a novel molecular signature, including miR-223, miR-93 and miR-532, as circulating marker endowed with high selectivity and specificity. The oncogenic effect and the prognostic significance of each miRNA was investigated by bioinformatic analysis, denoting significant correlation with OS. To analyse the molecular basis underlying the pro-tumorigenic role of the signature, we focused on the simultaneously regulated gene targets-IL6ST, GTDC1, MAP1B, CPEB3, PRKACB, NFIB, PURB, ATP2B1, ZNF148, PSD3, TBC1D15, PURA, KLF12-found by prediction tools and deepened for their functional role by pathway enrichment analysis. The results showed the involvement of 7 different biological processes, among which inflammation, proliferation, migration, apoptosis and angiogenesis.

conclusionsIn conclusion, we have identified a possible miRNA signature for early LSCC diagnosis and we assumed that miR-93, miR-223 and miR-532 could orchestrate the regulation of multiple cancer-related processes. These findings encourage the possibility to deepen the molecular mechanisms underlying their oncogenic role, for the desirable development of novel therapeutic opportunities based on the use of short single-stranded oligonucleotides acting as non-coding RNA antagonists in cancer.

Indexed as

Carcinoma, Squamous CellComputational BiologyEarly Detection of CancerGene Expression Regulation, NeoplasticLaryngeal NeoplasmsMicroRNAsAgedBiomarkers, TumorCase-Control StudiesFemaleGene Expression ProfilingGene Regulatory NetworksHumansKaplan-Meier EstimateMaleMiddle AgedBiomarkers, TumorMicroRNAsCancerGene targetsLaryngeal Squamous Cell CancermiR-223miR-532miR-93miRNAmiRNA signatureOverall survivalROC curve

Identifiers

PMID38987822
PMCPMC11238506

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.